RWHAP 2023 Breakout-Sessions
Meet-the-Expert Breakout Session registration is open for the 2023 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE for approved registered attendees. To register for your sessions, please click the link below and follow the prompts to register for a session for each day. There will be 15 sessions offered from December 3 to 5. Registration (more…)
The 2023 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
The 2023 RWHAP CLINICAL CONFERENCE will be in-person only. There will not be a virtual component. The deadline to apply is November 17, 2023. This conference is exclusively reserved for clinical decision makers (MD/DOs, PAs, and NPs) in RWHAP-funded programs or clinics. This activity is eligible for CME credits, ABIM MOC (more…)
The Annual IAS–USA Washington, DC, Virtual Course: Update on HIV Medicine Emerging Challenges
Last Modified: Program Description This comprehensive half-day virtual course will explore the emerging challenges in HIV medicine, including a discussion of the implications of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study, extending the discussion beyond the primary data. Topics include crucial (more…)
(Part 5 of 6) Substance Use Disorder: Stimulant Use Disorder, Harm Reduction, and Contingency Management in Patients With HIV
Overview Assessment of Needs Substance use disorders, including stimulant use disorders, may disproportionately affect people with HIV. It is essential that clinicians who treat patients with HIV recognize the signs of stimulant use disorder and understand the current treatment options and challenges. Drug Enforcement Agency certificate holders are now required to complete 8 hours (more…)
Presentation and Pathogenesis of Long COVID
Overview Assessment of Needs Rapid advances in knowledge about the biologic mechanisms that cause COVID-19 and its symptoms require the ongoing attention of practitioners involved in direct patient care. This webinar will address the implications of new information on the pathogenesis of long COVID, including current and ongoing research and gaps in knowledge. Learning (more…)
(Part 6 of 6) Substance Use Disorder: Future Directions Focusing on Long-Acting Injectable Buprenorphine
Overview Assessment of Needs Substance use disorders may disproportionately affect people with HIV. It is essential that clinicians who treat patients with HIV recognize the signs of substance use disorder and understand the current treatment options and challenges. Drug Enforcement Agency certificate holders are now required to complete 8 hours of training on opioids, (more…)
Basic Principles and Clinical Relevance of the IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1
Overview Assessment of Needs This webinar is useful for those who wish to utilize the IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1 for the management of antiretroviral therapy (ART) in their patients with HIV. This webinar will review the principles of HIV drug resistance mutations and summarize what is currently known about resistance to (more…)
Substance Use Disorder Webinar Series: Bonus Question-and-Answer Session
Overview Assessment of Needs The 6-part IAS–USA webinar series on substance use disorder (SUD), designed by expert faculty Sandra A. Springer, MD, and Ellen F. Eaton, MD, has been a resounding success, with the first 5 webinars now available on-demand and webinar 6 open for registration (see below for more information). Due to the (more…)
No Mo FOMO—In Case You Missed It: Recent Changes in Guidelines, New Publications, and Updates From Recent Conferences
Overview Assessment of Needs The management and treatment of patients with HIV constantly evolves as new data are presented at conferences and published in scholarly journals. This webinar summarizes current and new data on the HIV epidemic, including data from recent clinical trials and updates from recent conferences. Topics include the management of people (more…)
Mpox: Where Are We Now?
Overview Assessment of Needs Mpox illnesses, including severe infections, continue to occur across the United States and around the world. According to the Centers for Disease Control and Prevention, people with HIV-associated immunosuppression and people with HIV who are not virologically suppressed can be at increased risk of severe mpox. This webinar will provide an update on what clinicians need to know regarding (more…)